Akash Rusia
Advanced Heart Failure and Transplant Cardiology · Plano, TXNPI 1114314978
Payments from drug & device makers
What this record shows
This record is dominated by grants: $7,875 of the $12,646 with a category attached, or 62.3%. Abbott accounts for 81.6% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2022 at $9,830 and has fallen 93.5% since, to $635 in 2025. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in TX, where the typical reported total is $11,093.
Across 99 payments — averaging $127.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$10K
- Abiomed$292
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$233
- E.r. Squibb & Sons, L.L.C.$228
- Boehringer Ingelheim$187
- Edwards Lifesciences$181
- plus $1K from 18 others
What the payments were for
- Grants$7,87562%
- Travel & lodging$5584%
- Food & beverage$3,79630%
- Education$4183%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 31 | $10,319 |
| Abiomed | 2 | $292 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $233 |
| E.r. Squibb & Sons, L.L.C. | 6 | $228 |
| Boehringer Ingelheim | 4 | $187 |
| Edwards Lifesciences | 1 | $181 |
| Merck | 8 | $171 |
| Heartflow, Inc. | 3 | $147 |
| Amgen | 1 | $129 |
| Novo Nordisk | 6 | $129 |
| AstraZeneca | 6 | $115 |
| Novartis | 4 | $105 |
| Cvrx, Inc. | 2 | $69 |
| Lexicon Pharmaceuticals, Inc. | 3 | $65 |
| Scpharmaceuticals Inc. | 3 | $55 |
| Pfizer | 2 | $41 |
| Medtronic | 1 | $38 |
| Inspire Medical Systems, Inc. | 1 | $36 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Johnson & Johnson | 1 | $18 |
| Bayer | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
| Bridgebio Pharma, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,646 in reported general payments places this provider in the 50th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.
See all advanced heart failure and transplant cardiology providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 26 | $580,977 |
| EntrestoSacubitril/Valsartan | 176 | $256,605 |
| CamzyosMavacamten | 23 | $188,385 |
| JardianceEmpagliflozin | 96 | $106,851 |
| FarxigaDapagliflozin Propanediol | 103 | $100,875 |
| EliquisApixaban | 26 | $28,699 |
| Isosorbide Dinitrate | 17 | $10,060 |
| Torsemide | 89 | $2,506 |
| Spironolactone | 228 | $2,011 |
| Bumetanide | 33 | $1,774 |
| Metoprolol Succinate | 128 | $1,735 |
| Milrinone Lactate | 18 | $1,442 |
| Eplerenone | 12 | $991 |
| Carvedilol | 83 | $837 |
| Losartan Potassium | 80 | $779 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $41 | $609,67652 claims |
| NovartisEntresto | $105 | $256,605176 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $228 | $188,38523 claims |
| Boehringer IngelheimJardiance | $187 | $106,85196 claims |
| AstraZenecaFarxiga | $115 | $100,875103 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.
Other advanced heart failure and transplant cardiology in Plano
- Aasim AfzalPlano$336K
- Nitin KabraPlano$68K
- Gregory MilliganPlano$7K
- Robert GottliebDallas$717K
- Albert HicksTemple$613K
- Allen AndersonSan Antonio$413K
- Martin BerkDallas$379K
- Kunjan BhattAustin$324K
- Barry TrachtenbergHouston$306K
- Shelley HallDallas$254K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.